Biography

Van Trung Chu was earned Ph.D. degree from the German Rheumatism Research Centre (DRFZ), Berlin where he studies B cell biology and followed by a postdoc working with Dr. Claudia Berek. His works focused to the survival niches of long-lived plasma cells and intestinal immunity. Chu joined the Max-Delbrück-Center for Molecular Medicine, Berlin in 2013 where he worked with Prof. Klaus Rajewsky. Since 2017, he was honored as the permanent researcher in the Berlin institute of Health /and the MDC. Recently Chu’s research focuses to genome engineering technologies, particularly CRISPR/Cas9 system and he has several years of CRISPR/Cas9-mediated gene correction experience. For the long perspective, he is interested to develop the CRISPR/Cas9-mediated gene therapy to cure inherited monogenic blood disorders through repairing mutations in autologous hematopoietic stem/progenitor cells and sequent transplantation of the corrected stem/progenitor cells into patients.